Current perspectives and the future of disease-modifying therapies in type 1 diabetes

doi:10.4239/wjd.v16.i1.99496

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (144)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-1)

Sum=104

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=22

Publishing Process of This Article

Item

Count

Browse

Download

Sum=14

Jan 15, 2025 (publication date) through Dec 2, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Diabetes. Jan 15, 2025; 16(1): 99496
Published online Jan 15, 2025. doi: 10.4239/wjd.v16.i1.99496

Open in New Tab Full Size Figure Download Figure

Figure 1 Immune-targets and immunotherapy in type 1 diabetes. Solid lines indicate stimulatory effect, red and dashed lines indicate inhibitory effect. Boxes contain names of medicines grouped according to their mechanisms of action and sites of action[1,2,5,9]. APC: Antigen presenting cells; G-CSF: Granulocyte colony stimulating factor; IL: Interleukin; TNF: Tumour necrosis factor; Treg(s): Regulatory T cell(s); CD: Cluster differentiating.

Citation: Mondal S, Pappachan JM. Current perspectives and the future of disease-modifying therapies in type 1 diabetes. World J Diabetes 2025; 16(1): 99496
URL: https://www.wjgnet.com/1948-9358/full/v16/i1/99496.htm
DOI: https://dx.doi.org/10.4239/wjd.v16.i1.99496